Andrey Mladentsev joined Peter Bely's pool of advisers

12.04.2021

Corporate

Andrey Mladentsev left the post of Executive Director of PROMOMED Group to focus on investment management, while remaining in the pool of strategic development advisers to Chairman of the Board of Directors Peter Bely.


With his departure, the company's management structure will not change. The strategic management of the Group is still carried out by its shareholder Peter Bely, the plant of JSC Biochemik (part of the PROMOMED Group) is headed by Executive Director Dmitry Zemskov, the company PROMOMED DM LLC is headed by CEO Maxim Smagin.


Andrey Mladentsev was invited to the position of Executive Director of PROMOMED Group in June last year to strengthen the team for the launch of production of Areplivir, a new domestic drug to combat coronavirus infection. The drug was successfully launched in early autumn 2020 and is currently one of the most effective and safe medicines in the fight against the SARS-CoV-2 virus. Up to 2 million packages of Areplivir are produced monthly at the Saransk plant of JSC Biochemik. The drug is included in the list of medicines recommended by the Ministry of Health for the treatment of COVID-19, and is included in the list of vital and essential medicines.


Get the most interesting news and publications first!

Sent successfully!

Pharmacovigilance

Press office

To request a press release or interview, please contact our press office